Collaboration Agreements - Additional Information (Details) - USD ($)	1 Months Ended			3 Months Ended			6 Months Ended
	Jan. 31, 2021	Dec. 31, 2019	Jun. 30, 2019	May 31, 2022	Feb. 28, 2022	May 31, 2021	May 31, 2022	May 31, 2021	Aug. 31, 2022	Nov. 30, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration revenue				$ 11,432,000		$ 7,091,000	$ 21,053,000	$ 12,102,000
Deferred revenue, current				41,319,000			41,319,000			$ 41,212,000
Gilead Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment			$ 45,000,000.0
Upfront payment of additional fees			3,000,000.0
Research milestones payments received							30,500,000
Variable consideration included in transaction price			$ 32,000,000.0
Collaboration agreement contract term					5 years
Collaboration revenue				6,100,000		3,700,000	12,300,000	6,500,000
Collaboration revenue recognized from opening contract liability				5,300,000		2,900,000	8,600,000	5,600,000
Performance obligation satisfied				600,000		600,000	3,100,000	600,000
Recorded deferred revenue				34,800,000			34,800,000			41,100,000
Deferred revenue, current				17,000,000.0			17,000,000.0			19,900,000
Accounts receivable										6,000,000.0
Contract asset unbilled amount				1,500,000			1,500,000
Gilead Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment of additional fees receivable				2,300,000			2,300,000
Gilead Agreement | Scenario Forecast
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Recognized research milestone payments to be received									$ 1,500,000
Sanofi Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment	$ 55,000,000.0	$ 55,000,000.0
Research milestones payments received							3,000.0
Variable consideration included in transaction price	3,000,000.0
Collaboration revenue recognized from opening contract liability				5,300,000		3,300,000	8,200,000	5,600,000
Performance obligation satisfied							0	500,000
Recorded deferred revenue				52,400,000			52,400,000			59,200,000
Deferred revenue, current				24,300,000			$ 24,300,000			$ 21,300,000
Additional payment received to exercise option to expand number of targets	$ 22,000,000.0
Contractual initial research period							4 years 3 months
Collaboration revenue				5,300,000		$ 3,300,000	$ 8,700,000	$ 5,600,000
Sanofi Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payments additional fees receivable				$ 2,500			$ 2,500